Overcoming Complications in Cross-Border Licensing Deals with China

Partnering activity in China continued to accelerate in 2021 with 658 deals generating a record $42 billion in deal value, and over 50% of the cross border deals being done with U.S. companies and 25% with EU companies. However, the pandemic and geopolitical tensions have complicated negotiating and closing deals recently.  The panel will discuss successful practices for identifying and pursuing cross-border licensing deals in the current climate so new medicines will be able to reach patients both inside China and around the world faster.